The sector is expected to hit $553.8m by 2034.
The growing integration of genetic testing into national healthcare frameworks is driving the Asia Pacific’s Gaucher disease treatment market to reach $553.8m by 2034 at a compound annual growth rate of 3.2%, according to Polaris Market Research.
Governments and healthcare institutions in major economies are introducing programmes to expand newborn screening and early diagnostics for lysosomal storage disorders, such as Gaucher disease.
“In recent years, rising awareness and increased funding for rare diseases have begun reshaping the landscape of Gaucher disease care in countries such as China, Japan, and South Korea,” the report said.
Moreover, accessibility to enzyme replacement therapies (ERT) is also expanding across the region.
“Governments in countries like China have added ERT drugs such as imiglucerase and velaglucerase alfa to their National Reimbursement Drug Lists,” it added.
Gaucher disease is a rare, lifelong genetic disorder, characterised by a lack of the “glucocerebrosidase” enzyme, which leads to a build-up of fatty substances in the bone marrow, spleen, liver and nervous system.
